reports
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Clene to Participate in a Panel Discussion at the Maxim Growth Summit SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor mee...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CNM-Au8® improved the brain’s energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligne...
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment ...
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease Results presented today at the H2 Therapeutics Stewardship Meeting in New York City, hosted by the Michael J Fox Foundation Taken together with results from a Phase 2 study that demonstrated orally dosed CNM-Au8 favorably alters cri...
Clene to Present at the H.C. Wainwright 27th Annual Global Investment ...
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor meetings. Date...
Clene Reports Second Quarter 2025 Financial Results and Recent Operati...
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosingThe Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALSA Type B end-o...
Clene to Present at the Emerging Growth Conference
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 20, 2025Time of Presentation: 2:20 p.m. ETFormat: Corporate ...
Clene to Present at the Canaccord 45th Annual Growth Conference
Clene to Present at the Canaccord 45th Annual Growth Conference SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings. Date: August 12th, 2025Time of Presen...
- David Nierengarten
- Dennis Pak
- Martin Fan
Clene Provides Regulatory Update Following Constructive FDA Type-C Mee...
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3rd Quarter of 2025, to discuss ALS survival data and MS clinical development programSubmission of new drug application for ALS under the accelerated a...
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of ...
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take s...
Psychemedics Releases 2025 Workforce Insights Report
Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
BBDC BARINGS BDC INC.
ENR EDGEWELL PERSONAL CARE COMPANY
INZY INOZYME PHARMA
ALIT ALIGHT
WEST INC. / DELAWARE
STRW WESTROCK COFFEE COMPANY LLC
SRBK STRAWBERRY FIELDS REIT INC.
SDHC SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO EATON VANCE INSD CALIF MUN BD FD
GF MORNINGSTAR PARTNERS
GREE L.P.
HCWB THE NEW GERMANY FUND
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLUG PLUG POWER INC.
MAIN MAIN STREET CAPITAL CORPORATION
PATK PATRICK INDUSTRIES INC.
ELY CALLAWAY GOLF COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
FLWS 1-800-FLOWERS.COM CL A
SNDX SYNDAX PHARMACEUTICALS
NNBR NN
OCSL INC.
MPB OAKTREE SPECIALTY LENDING CORPORATION
ENR MID PENN BANCORP INC.
ZYME EDGEWELL PERSONAL CARE COMPANY
ARQT ZYMEWORKS INC.
HQL ARCUTIS BIOTHERAPEUTICS
ADV INC.
CVRX TEKLA LIFE SCIENCES INVESTORS
SRPT ADVANTAGE SOLUTIONS INC (A)
DMA CVRX
SUNS INC.
EVM SAREPTA THERAPEUTICS
TXO INC.
GF DESTRA MULTI ALTERNATIVE FUND
FG SUNRISE REALTY TRUST
IAE EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
- Jonathan Moreland
CMI CUMMINS INC.
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
OEC ORION ENGINEERED CARBONS SA
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
BRKR BRUKER CORPORATION
ASYS AMTECH SYSTEMS INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
GCBC GREENE COUNTY BANCORP INC.
WINA WINMARK CORP.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
LILA INC.
COLD LIBERTY LATIN AMERICA A
EAF AMERICOLD REALTY TRUST
ULBI GRAFTECH INTERNATIONAL
MIDD ULTRALIFE
ENR THE MIDDLEBY CORPORATION
RPAY EDGEWELL PERSONAL CARE COMPANY
PRG REPAY HOLDINGS (A)
LESL PROG HOLDINGS
GRNT INC.
ALKT LESLIES
CVRX GRANIT SKOPKE
MINM ALKAMI TECHNOLOGY
MYO INC.
FLNC CVRX
DCGO INC.
STGW MINIM
OGN INC.
PFHC MYOMO
RXO_w FLUENCE ENERGY INC
OABI DOCGO INC
WEST STAGWELL INC
SRPT ORGANON & CO
FTK PROFRAC HLDG CORP
TXO RXO INC
AESI OMNIAB INC
FINS WESTROCK COFFEE COMPANY LLC
SAREPTA THERAPEUTICS
INC.
FLOTEK INDUSTRIES INC.
MORNINGSTAR PARTNERS
L.P.
ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Psychemedics Named “Most Innovative Drug Testing Company of the Year”
Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
LTRX LANTRONIX INC.
BRKR BRUKER CORPORATION
OFIX ORTHOFIX INTERNATIONAL N.V.
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
THS TREEHOUSE FOODS INC.
WINA WINMARK CORP.
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
HAIN INC.
SNBR THE HAIN CELESTIAL GROUP
LILA INC.
COLD SLEEP NUMBER CORPORATION
ULBI LIBERTY LATIN AMERICA A
MIDD AMERICOLD REALTY TRUST
CCO ULTRALIFE
PRG THE MIDDLEBY CORPORATION
LESL CLEAR CHANNEL OUTDOOR HOLDINGS INC
KLXE PROG HOLDINGS
CVRX INC.
MYO LESLIES
SEAT KLX ENERGY SERVICES
DCGO CVRX
PFHC INC.
MYOMO
VIVID SEATS INC.
DOCGO INC
PROFRAC HLDG CORP
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provid...
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Ino...
- David Nierengarten
- Dennis Pak
- Martin Fan
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.